An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Advanced Solid Tumor
Lymphoma

Interventions

DRUG: ALPN-202

Sponsor

Alpine Immune Sciences, Inc.